

617

POSTER

HER2 cytoplasmic staining as an independent risk factor for death in penile cancer

A.M.T. Silva¹, R.M. Rocha¹, I.W. Cunha¹, A. Cubilla², G.C. Guimarães³, A. Lopes³, F.A. Soares¹. ¹Hospital AC Camargo, Anatomia Patológica, São Paulo, Brazil; ²Universidad Nacional de Asunción, Anatomia Patológica, Asunción, Paraguay; ³Hospital AC Camargo, Cirurgia Pélvica, São Paulo, Brazil

Background: Although rare in developed regions, penile carcinoma is a serious concern for undeveloped countries such as Brazil, where it can represent up to 10% of all malignancies. HER2 is a well-known growth factor membrane receptor that has its high protein expression levels usually associated with aggressive disease. Recently, some studies have shown that soluble fractions of HER2 intracellular domain are found in tumors cytoplasm and there they can still activate intracellular pathways related to cell proliferation and survival.

Material and Methods: Immunohistochemistry against HER2 was carried out in 195 penile carcinoma samples selected from the files of AC Camargo Hospital, Brazil, using the monoclonal CB11 antibody (Novocastra™), which recognizes specifically HER2 intracellular domain. Cases were classified as positive or negative according to membrane and to cytoplasmic staining. All statistical analyses were performed by the SPSS for Windows 18.0, SPSS Inc. Comparisons between category variables was performed by Pearson chi-square test or Fisher's exact test. Survival rates were calculated using the Kaplan-Meier method and the curves were compared by means of the log-rank test. In all statistical tests, the alpha error was set at 5%.

Results: None of the cases showed membrane staining for HER2. However, a clear and strong cytoplasm staining was observed in 28 cases (14.9%), as shown in figure 1. The staining was limited to the tumor cells and does not represent background or artifact. Univariate analyses showed that this expression pattern is associated with higher histologic grade ($p < 0.001$) and lower overall survival ($p = 0.007$). Multivariate analyses showed that HER2 in the cytoplasm is an independent risk factor for death (RR = 2.966; 95% CI [1.6–5.2]; $p < 0.001$).




Figure 1 – Cytoplasmic staining of HER2 in penile carcinomas.

Conclusions: Corroborating with recent findings that cytoplasmic fragments of HER2 can be active kinases, the present study demonstrates that the presence of HER2 in tumor cytoplasm is a prognostic marker in penile carcinoma. We have also demonstrated that, although no membrane staining was seen, presence of HER2 in cytoplasm is an independent risk factor for death in this neoplasm.

618

POSTER

Biological correlation of the expression EGFR pathway in renal cell carcinoma with Hif1- α , VEGF, VEGFR-2(Fik-1), TGF- α , VHL in tumor tissue sample levels

M. Vanessa¹, G. Aparicio Gallego¹, I. Santamarina Caínzos¹, M. Quindós Varela², D. Dopico Vázquez², R. García Campelo², G. Alonso-Jaudenes Curbera², L. Valbuena Rubira³, E. Grande Pulido⁴, L.M. Antón Aparicio⁵. ¹INIBIC (CHU A Coruña), Oncology, La Coruna, Spain; ²CHU A Coruña, Medical Oncology, La Coruna, Spain; ³CHU A Coruña, Pathology, La Coruna, Spain; ⁴Ramón y Cajal Hospital, Oncology, Madrid, Spain; ⁵University of A Coruña, Medical Department, A Coruña, Spain

Background: Signal transduction triggers when cells respond to external stimuli. There is a not yet well understood intracellular crosstalk between different signal transduction pathways. The epidermal growth factor receptor (EGFR) pathway is one among the many pathways implicated in renal cell carcinoma (RCC) oncogenesis and leads to cell proliferation, motility, and survival. This work focuses on the signalling network formed by the interaction of the EGFR signalling pathway and those in which are involved: Hif1- α , VEGF, VEGFR-2, TGF- α and VHL tumor suppressor gene.

Material and Methods: For its purpose this study investigated the pattern of protein expression in RCC specimens using tissue-array

(TA) technology. We retrospectively analyzed 80 paraffin-embedded RCC samples: 16 chromophobe RCC (ccRCC), 4 papillary RCC (pRCC), 58 clear cell RCC (ccRCC) and 2 identified as unknown histological type (UNK). The immunohistochemical data of molecular factors were correlated by means of two non-parametric rank-based statistical tests: Pearson's correlation coefficient test and Spearman's rho test.

Results: EGFR reaction was detected in the membrane in 75% of cases. The remaining 25% presented a dual localization: membrane and cytoplasm. Cases that showed higher expression with were those falling within the ccRCC histological type ($p = 0.001$). We found that VEGFR-2 showed significant negative correlation with Hif1- α and EGFR ($r = -0.448$ and $r = -0.364$, sig. 0.01 respectively). Hif1- α presented a significant positive correlation with EGFR and VEGF ($r = 0.291$ and $r = 0.277$ with a sig. level of $p = 0.009$ and $p = 0.014$ respectively). Finally we found a significant positive correlation between TGF- α and EGFR (Spearman's rho = 0.222, sig. level 0.05).

Conclusions: The observation that ccRCC specimens exhibit EGFR at higher levels when compared histological subtypes may be helpful in diagnosis. HIF1- α and EGFR are key events during development and progression of RCC, which act in regulating tumor angiogenesis as well, and show intimate relationship with biological behaviour. Molecular findings need to be correlated with clinical features.

619

POSTER

Tissue array study in renal cell carcinoma: Hif1- α , CAIX and VEGF correlation

M. Vanessa¹, G. Aparicio Gallego¹, I. Santamarina Caínzos¹, M. Quindós Varela², D. Dopico Vázquez², R. García Campelo², M. Valladares-Ayerbes², L. Valbuena Rubira³, E. Grande Pulido⁴, L.M. Alonso-Jaudenes Curbera⁵. ¹INIBIC (CHU A Coruña), Oncology, La Coruna, Spain; ²CHU A Coruña, Medical Oncology, La Coruna, Spain; ³CHU A Coruña, Pathology, La Coruna, Spain; ⁴Ramón y Cajal Hospital, Medical Oncology, Madrid, Spain; ⁵University of A Coruña, Medical Department, A Coruña, Spain

Introduction: Recent progresses in the basic sciences have led to an increased understanding of the molecular pathways underlying the various renal cell carcinoma (RCC) subtypes. Hypoxia-inducible factor 1 α plays a key role in RCC. Hif1- α regulates angiogenesis, tumor growth, progression, metastatic spread, and glucose metabolism by acting as a transcription factor for crucial proteins such as vascular endothelial growth factor (VEGF) and carbonic anhydrase IX (CAIX). The purpose of this work is evaluated the significance of these molecules in RCC.

Methodology: We retrospectively analyzed 80 paraffin-embedded RCC samples. We studied the pattern of protein expression by tissue-array (TA) technology. Immunohistochemical (IHC) reaction was visualized by the Dako En Vision system and diaminobenzidine. Immunoreaction was rated semiquantitatively by percentage of positive cells and staining intensity on immunohistological stainings. The expression levels were associated with pathological variables.

Results: A 46.3% of the samples showed a maximum score (+++ average expression cell/tissue from 80%) for Hif1- α . 27% of the samples showed a moderate positivity (++). We visualized cytoplasm localization in 100% of positive samples. Hif1- α expression was greater in clear cell RCC (ccRCC) subtype (Kruskal-Wallis test $p < 0.001$), in those cases which presented renal pelvis invasion (Kruskal-Wallis test $p = 0.023$) and moreover its expression increased as the number of involved nodes (Kruskal-Wallis test $p < 0.001$). VEGF expression was characteristic for papillary RCC subtype, Fuhrman Grade III and when there were metastases in more than one regional lymph node (Kruskal-Wallis test $p = 0.009$, $p = 0.029$ and $p < 0.001$ respectively). For CAIX we could observe higher expression in ccRCC ($p < 0.001$). Regarding the correlations between the markers we can say that HIF1- α showed significant positive correlation with VEGF and CAIX (Spearman's rho = 0.391 sig. 0.01 and Spearman's rho = 0.304 sig. 0.01 respectively).

Conclusions: These results suggest that these markers may be useful for diagnosis in RCC. Hif1- α and VEGF seems to appear as a markers of poor prognosis. Further studies are needed to clarify the role of these molecules in RCC.

620

POSTER

Discordant expression patterns of four different CD133 antibody clones in glioblastomas – possible implications for CD133 as a new therapeutic target

S.K. Hermansen¹, K.G. Christensen¹, S.S. Jensen¹, B.W. Kristensen¹. ¹University of Southern Denmark, Department of Pathology, Odense, Denmark

Brain tumor stem cells are obvious new therapeutic targets because of their role in initiation and progression of brain tumors. As the putative

tumor stem cell marker CD133 is the marker of choice for identifying brain tumor stem cells in gliomas, CD133 has become a new target candidate for antibody-mediated therapy. However, the use of different anti-CD133 antibody clones possibly recognizing different CD133 splice variants with epitopes of different glycosylation status confuses the field. Furthermore, a dynamic CD133 tertiary structure has been proposed to render epitopes inaccessible in differentiating cells. All these factors are important when considering CD133 for future immunotherapy.

In the present study, we hypothesized that the use of different CD133 antibodies for identification of CD133 would yield discordant results. We investigated this using paraffin embedded sections of glioblastoma, kidney, pancreas and placenta tissue as well as glioblastoma and retinoblastoma cell lines. This material was stained with four different CD133 antibody clones and analyzed using light microscopy. In glioblastomas, ten consecutive tumors were analyzed using quantitative stereology on stainings of adjacent sections with each of the four CD133 clones.

Results revealed presence of CD133⁺ niches in glioblastomas, often in close relation to blood vessels, using all four antibody clones. The distribution of identified niches did, however, rarely correspond among each antibody clone. Staining of glioblastoma single and niche cells was predominantly cytoplasmic, which is opposed to the membranous staining observed in epithelial cells in kidney, pancreas and placenta tissues. Stereology revealed vast dissimilarities regarding fractions of CD133⁺ niches and single cells among the CD133 antibody clones.

In conclusion, we report that discordant results are obtained when using different CD133 antibodies for identification of CD133⁺ cells in paraffin sections, thereby possibly explaining current discordant CD133 observations in the literature. This may have important implications for CD133 as a new therapeutic target since it is not clear which tumor cell populations the different CD133 clones identify. Future CD133 immunotherapy should thus include comprehensive characterization of epitopes, splice variants and influence of differentiation on CD133 tertiary structure.

621

POSTER

The three-dimensional FISH with IHC can work on circulating tumor cells

Y. Mishima¹, Y. Terui¹, S. Matsusaka¹, Y. Mishima¹, K. Hatake¹.

¹Japanese Foundation for Cancer Research, Cancer Chemotherapy Center, Tokyo, Japan

Background: Circulating tumor cells (CTCs) offer a non-invasive approach to characterize metastatic tumor cells. However, the low recovery rates of CTCs by methods performed in most clinical laboratory have limited their usefulness. Recent studies have suggested that discordance may exist between Her-2 status of a patient's CTC and that of primary breast tumor. To investigate Her-2 status in detail, we developed a new technique of the FISH analysis of CTCs. Most CTCs enrichment techniques are anti-EpCAM antibody based. However, some tumor cells express low or no EpCAM. So, we adopted the strategy independent of EpCAM antigenicity in order to reliably analyze genes even with very few CTCs.

Material and Methods: The method for Her-2 analysis that we established was based on three-dimensional multi-color imaging. Briefly, CTCs of tumor patients were concentrated by negative selection from peripheral blood by using antibodies against WBC, RBC, and platelets. The concentrated CTCs were labeled by fluorescent monoclonal antibodies against pan-cytokeratin and CD45. The specimens were then hybridized with FISH probes and were mounted in DAPI with antifade reagent. The preparations were screened for a series of Z-axis optical sections with a confocal microscope. To inspect the availability of our method, we analyzed the peripheral blood or effusion specimens of patients with gastrointestinal tumor. The study was approved by the Institutional Review Board of Japanese foundation for Cancer Research.

Results: CTCs (Cytokeratin+/CD45-/DAPI+) were easily discriminated from remaining hematopoietic cells (CD45+). And these immunocytochemical staining had no crossover on FISH signal by the benefit of confocal imaging. In addition, three-dimensional imaging reconstruction enabled counting of three-dimensional single signals, distinguishing between overlapping three-dimensional signals in three-dimensional single nuclei. Recovery rates of tumor cells spiked into normal blood averaged 79%. With the peritoneal/pleural effusion samples, the recovery rates of cytokeratin positive cells were significantly higher compared to conventional method using magnetic sorting by anti-EpCAM mAb (72% vs 9.2%, n = 6). Tumor cells in these effusion fluid expressed low or no EpCAM, so this discrepancy was considered to be caused by low EpCAM expression.

Conclusions: High recovery rate of CTCs and three-dimensional imaging made it possible to analyze Her-2 gene status easily and accurately. Using this methods, we are currently working on the investigation of Her-2 state in CTCs derived from patients with gastrointestinal tumor and its relation of treatment prognosis.

622

POSTER

Detection of genetic alterations in patients with hepatocellular carcinoma (HCC) in Coimbatore population

S. Mohana Devi¹, B. Vellingiri¹, A.R.U.N. Meyyalagan¹, K. Alagamuthu¹, M. Pappusamy¹, S. Keshavarao¹, ¹Bharathiar University, Human Molecular Genetics, Coimbatore Tamilnadu, India

Hepatoma or Hepatocellular Carcinoma (HCC) is the fourth leading cause of cancer deaths in the world. Hepatoma is one of the most common and highly malignant tumour worldwide, with a high incidence in developing country. The aim of the present study was to identify the Chromosomal aberrations in hepatoma patients to assess whether peripheral blood had non-random cytogenetic aberrations as observed in tumor samples. The study was conducted on the peripheral blood of 65 hepatoma patients (aged 30 to 85 years male) undergoing hepatic resection of liver tumour with curative intent. In the present study all the experimentals and controls were analysed chromosomal alterations using conventional G-banding. We sought to identify those changes that may be associated with development and progression of HCC. In the present investigation, HCC patients had significantly increased aberrant metaphases compared to controls. Hepatoma samples revealed frequent aberrations in chromosomes 1, 8, 17, 13, 16 and 20. Our finding of a high incidence of 1q gain and frequent deletion in the short arm of chromosome 8 strongly suggested this aberration was associated with the development of this disease. Chromatid breaks were seen on chromosomes 1, 2, and 4 while chromatid gaps were on chromosomes 1, 2 and 3. The identified altered chromosomal regions may harbour tumour suppressor genes or Oncogenes that are involved in the multistep process of carcinogenesis or disease pathology. Aberrations of diverse sites indicate that the patients probably have a constitutional chromosomal instability which participates in cancer predisposition and there is involvement of some common genes in tumor initiation and development. The results of this study might help in providing important clues and to add better knowledge in the location of relevant genes on specific altered regions of chromosomes. Comprehensive elucidation of the specific genes and molecular pathways involved in progression from pre neoplastic lesion to frank neoplastic in the protracted process of hepatocarcinogenesis will facilitate development of new strategies for prevention and therapy. Identification of molecular pathways that drive the proliferation of neoplastic hepatocytes may enable development of drugs that can specifically target and kill those cells.

623

POSTER

FDG PET/CT as an imaging biomarker for patients with metastatic renal cell carcinoma

N. Nakaigawa¹, M. Yao¹, R. Minamimoto², K. Namura¹, K. Makiyama¹, D. Ueno¹, A. Sakata¹, J. Kasuga¹, T. Inoue², Y. Kubota². ¹Yokohama City University Graduate School of Medicine, Department of Urology, Yokohama, Japan; ²Yokohama City University Graduate School of Medicine, Department of Radiology, Yokohama, Japan

Background: In this era of molecular targeting therapy when various systematic treatments can be selected, prognostic biomarkers are required for the purpose of risk-directed therapy selection. Numerous reports of various malignancies have revealed that 18-Fluoro-2-deoxy-D-glucose (¹⁸F-FDG) accumulation, as evaluated by positron emission tomography, can be used to predict the prognosis of patients. The purpose of this study was to evaluate the impact of the maximum standardized uptake value (SUVmax) from 18-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (¹⁸F-FDG PET/CT) on survival for patients with advanced renal cell carcinoma (RCC).

Methods: A total of 26 patients with advanced or metastatic RCC were enrolled in this study. The FDG uptake of all RCC lesions diagnosed by conventional CT was evaluated by ¹⁸F-FDG PET/CT. The impact of SUVmax on patient survival was analyzed prospectively.

Results: FDG uptake was detected in 230 of 243 lesions (94.7%) excluding lung or liver metastases with diameters of less than 1 cm. The SUVmax of 26 patients ranged between 1.4 and 16.6 (mean 8.8±4.0). The patients with RCC tumors showing high SUVmax demonstrated poor prognosis (P=0.005 hazard ratio 1.326, 95% CI 1.089–1.614). The survival between patients with SUVmax equal to the mean of SUVmax, 8.8 or more and patients with SUVmax less than 8.8 were statistically different (P=0.0012). Multivariate analysis with classical risk factors revealed that SUVmax was an independent prognostic factor (P=0.032). SUVmax demonstrated a tendency to predict the survival compared with the Memorial Sloan-Kettering Cancer Center classification (P=0.070 vs 0.12). This is the first report to evaluate the impact of SUVmax on advanced RCC patient survival. However, the number of patients and the follow-up period were still not extensive enough to settle this important question conclusively.